Janssen, MacroGenics sign potential $575m+ licensing deal
This article was originally published in Scrip
Executive Summary
Janssen Biotech, a unit of Johnson and Johnson, has struck a licensing deal with clinical-stage biopharma MacroGenics for the development of the latter firm's CD19-directed therapy, MGD011.